The precision of regression-type estimator for incremental cost-effectiveness ratio

被引:0
|
作者
Wu, Chien-Hua [1 ]
Wan, Shu-Mei [2 ]
机构
[1] Chung Yuan Christian Univ, Dept Appl Math, Chungli 32023, Taiwan
[2] Lunghwa Univ Sci & Technol, Dept Finance, Tao Yuan 333, Taiwan
关键词
clinical trials; econometric models; pharmaceutical statistics; point processes; CONFIDENCE-INTERVALS; UNCERTAINTY;
D O I
10.1080/00949655.2011.572073
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The estimation of incremental cost-effectiveness ratio (ICER) has received increasing attention recently. It is expressed in terms of the ratio of the change in costs of a therapeutic intervention to the change in the effects of the intervention. Despite the intuitive interpretation of ICER as an additional cost per additional benefit unit, it is a challenge to estimate the distribution of a ratio of two stochastically dependent distributions. A vast literature regarding the statistical methods of ICER has developed in the past two decades, but none of these methods provide an unbiased estimator. Here, to obtain the unbiased estimator of the cost-effectiveness ratio (CER), the zero intercept of the bivariate normal regression is assumed. In equal sample sizes, the Iman-Conover algorithm is applied to construct the desired variance-covariance matrix of two random bivariate samples, and the estimation then follows the same approach as CER to obtain the unbiased estimator of ICER. The bootstrapping method with the Iman-Conover algorithm is employed for unequal sample sizes. Simulation experiments are conducted to evaluate the proposed method. The regression-type estimator performs overwhelmingly better than the sample mean estimator in terms of mean squared error in all cases.
引用
收藏
页码:1105 / 1114
页数:10
相关论文
共 50 条
  • [31] Incremental cost-effectiveness of initial cataract surgery
    Busbee, BG
    Brown, MM
    Brown, GC
    Sharma, S
    OPHTHALMOLOGY, 2002, 109 (03) : 606 - 612
  • [32] Statistical inference for cost-effectiveness ratio
    Laska, EM
    Meisner, M
    Siegel, C
    HEALTH ECONOMICS, 1997, 6 (03) : 229 - 242
  • [33] A Sensitivity Analysis of Incremental Cost-Effectiveness Ratio of the Nationwide Public Access Defibrillation Program in Japan
    Kaneko, Hiroshi
    Hatanaka, Tetsuo
    Nagase, Aki
    Marukawa, Seishiro
    Sakamoto, Tetsuya
    CIRCULATION, 2014, 130
  • [34] The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices
    Yuan, Fei
    Bangdiwala, Shrikant I.
    Tong, Wesley
    Lamy, Andre
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (01) : 69 - 78
  • [35] Non-parametric methods for estimating confidence intervals around the Incremental Cost-Effectiveness Ratio
    Petrinco, Michele
    Gregori, Dario
    Lazzarato, Fulvio
    Brunello, Franco
    Veltri, Andrea
    Berchialla, Paola
    Pagano, Eva
    EPIDEMIOLOGIA & PREVENZIONE, 2008, 32 (06): : 307 - 313
  • [36] Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives
    Trippoli, Sabrina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 43 : E36 - E36
  • [37] Analysis Indicates Low Incremental Cost-Effectiveness Ratio for Implementation of Lung Cancer Screening in Italy
    Veronesi, G.
    Ghislandi, S.
    Vanni, E.
    Dieci, E.
    Toschi, L.
    Velutti, L.
    Solinas, M.
    Novellis, P.
    Alloisio, M.
    Riboli, E.
    Navone, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S968 - S968
  • [38] A cceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
    Griffiths, Elizabeth A.
    Hendrich, Janek K.
    Stoddart, Samuel D. R.
    Walsh, Sean C. M.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 463 - 476
  • [39] Cost-effectiveness of precision medicine: a scoping review
    Kasztura, Miriam
    Richard, Aude
    Bempong, Nefti-Eboni
    Loncar, Dejan
    Flahault, Antoine
    INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2019, 64 (09) : 1261 - 1271
  • [40] WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS: HOW IGNORING THE MODEL'S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO
    Van Vlaenderen, I
    Moeremans, K.
    Van Bellinghen, L.
    VALUE IN HEALTH, 2018, 21 : S5 - S6